Vertex Pharmaceuticals (VRTX) — Fundamentals Overview

Vertex Pharmaceuticals marked a 3.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $311.26? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.

  • Vertex Pharmaceuticals belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07

  • The company's P/B ratio is 6.1

  • Vertex Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 24.0 based on its trailing 12 month price to earnings (EPS) of $12.99 per share

  • Its forward P/E ratio is 19.6, based on its forward earnings per share (EPS) of $15.85

  • VRTX has a Price to Earnings Growth (PEG) ratio of 2.2, which shows the company is overvalued when we factor growth into the price to earnings calculus.

  • Over the last four years, Vertex Pharmaceuticals has averaged free cash flows of $2,298,695,333.30, which on average grew 40.4%

  • Vertex Pharmaceuticals has moved 30.2% over the last year compared to -12.6% for the S&P 500 -- a difference of 42.9%

  • VRTX has an average analyst rating of buy and is -4.14% away from its mean target price of $324.7 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.